Sera Prognostics, Inc. (SERA)
USD 8.18
(-0.37%)
USD 8.18
(-0.37%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 96 Thousand USD | -1172.0% |
| 2022 | 75 Thousand USD | 66.67% |
| 2021 | 45 Thousand USD | 221.43% |
| 2020 | 14 Thousand USD | -22.22% |
| 2019 | 18 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -213 Thousand USD | -9.23% |
| 2024 Q2 | -344 Thousand USD | -61.5% |
| 2023 Q1 | 38 Thousand USD | 533.33% |
| 2023 FY | -804 Thousand USD | -1172.0% |
| 2023 Q3 | -2000.00 USD | -104.65% |
| 2023 Q2 | 43 Thousand USD | 13.16% |
| 2023 Q4 | -195 Thousand USD | -9650.0% |
| 2022 Q2 | 22 Thousand USD | 22.22% |
| 2022 Q1 | 18 Thousand USD | 50.0% |
| 2022 Q4 | 6000.00 USD | -79.31% |
| 2022 FY | 75 Thousand USD | 66.67% |
| 2022 Q3 | 29 Thousand USD | 31.82% |
| 2021 Q2 | 12 Thousand USD | 50.0% |
| 2021 FY | 45 Thousand USD | 221.43% |
| 2021 Q4 | 12 Thousand USD | -7.69% |
| 2021 Q1 | 8000.00 USD | 166.67% |
| 2021 Q3 | 13 Thousand USD | 8.33% |
| 2020 Q2 | 4000.00 USD | -20.0% |
| 2020 Q1 | 5000.00 USD | 0.0% |
| 2020 Q4 | 3000.00 USD | 50.0% |
| 2020 FY | 14 Thousand USD | -22.22% |
| 2020 Q3 | 2000.00 USD | -50.0% |
| 2019 FY | 18 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | 98.996% |
| Prenetics Global Limited | 8.82 Million USD | 98.913% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 99.195% |
| CareDx, Inc | 178.32 Million USD | 99.946% |
| Exact Sciences Corporation | 1.84 Billion USD | 99.995% |
| Exagen Inc. | 29.45 Million USD | 99.674% |
| Inotiv, Inc. | 165.44 Million USD | 99.942% |
| Guardant Health, Inc. | 336.89 Million USD | 99.972% |
| Biodesix, Inc. | 36.07 Million USD | 99.734% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | 92.779% |
| Precipio, Inc. | 6.01 Million USD | 98.405% |
| iSpecimen Inc. | 5.1 Million USD | 98.121% |
| Natera, Inc. | 492.74 Million USD | 99.981% |
| Aspira Women's Health Inc. | 5.26 Million USD | 98.176% |
| Standard BioTools Inc. | 50.45 Million USD | 99.81% |
| 23andMe Holding Co. | 99.37 Million USD | 99.903% |
| Castle Biosciences, Inc. | 174.8 Million USD | 99.945% |
| Personalis, Inc. | 18.2 Million USD | 99.473% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | 99.271% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | 98.265% |
| OpGen, Inc. | -90.69 Thousand USD | 205.85% |
| T2 Biosystems, Inc. | -8.17 Million USD | 101.175% |
| Myriad Genetics, Inc. | 476.4 Million USD | 99.98% |
| ICON Public Limited Company | 1.81 Billion USD | 99.995% |
| NeoGenomics, Inc. | 244.6 Million USD | 99.961% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 99.195% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 99.996% |
| RadNet, Inc. | 93 Million USD | 99.897% |
| MDxHealth SA | 43.92 Million USD | 99.781% |
| Psychemedics Corporation | 8.41 Million USD | 98.859% |
| Illumina, Inc. | 2.74 Billion USD | 99.997% |
| Check-Cap Ltd. | -212 Thousand USD | 145.283% |
| Twist Bioscience Corporation | 133.34 Million USD | 99.928% |
| DarioHealth Corp. | 5.98 Million USD | 98.396% |
| Fulgent Genetics, Inc. | 104.45 Million USD | 99.908% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 134.852% |
| OPKO Health, Inc. | 318.12 Million USD | 99.97% |
| Medpace Holdings, Inc. | 524.5 Million USD | 99.982% |
| Neogen Corporation | 463.9 Million USD | 99.979% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | 93.266% |
| Prenetics Global Limited | 8.82 Million USD | 98.913% |
| Mainz Biomed B.V. | 509.65 Thousand USD | 81.164% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | 87.873% |
| Trinity Biotech plc | 19.45 Million USD | 99.506% |
| Neuronetics, Inc. | 51.7 Million USD | 99.814% |
| Sotera Health Company | 577.15 Million USD | 99.983% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | 87.873% |